Search Results - "Keating Litton, Jennifer"

Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer by YENNURAJALINGAM, Sriram, FRISBEE-HUME, Susan, DALAL, Shalini, MASSIE, Lisa, REDDY, Suresh K, BRUERA, Eduardo, LYNN PALMER, J, DELGADO-GUAY, Marvin O, BULL, Janet, PHAN, Alexandria T, TANNIR, Nizar M, KEATING LITTON, Jennifer, REDDY, Akhila, HUI, David

“…Cancer-related fatigue (CRF) is the most common symptom in patients with advanced cancer. The primary objective of this prospective, randomized, double-blind,…”
Get full text

Exemestane in the prevention setting by Litton, Jennifer Keating, Bevers, Therese B., Arun, Banu K.

“…Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of…”
Get full text

Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience by ARUN, Banu, BAYRAKTAR, Soley, ALBARRACIN, Constance, LIU, Diane D, GUTIERREZ BARRERA, Angelica M, ATCHLEY, Deann, PUSZTAI, Lajos, LITTON, Jennifer Keating, VALERO, Vicente, MERIC-BERNSTAM, Funda, HORTOBAGYI, Gabriel N

“…To compare the pathologic complete response (pCR) rate and relapse-free survival (RFS) and overall survival (OS) after neoadjuvant systemic chemotherapy (NST)…”
Get full text

Is Age Still the Deciding Factor? Commentary on “The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer” by Partridge et al by Keating Litton, Jennifer

“…The study by Partridge et al., published in this edition of The Oncologist, is examined…”
Get full text

Examining progression free survival (PFS), overall survival (OS), and toxicities of palbociclib in a geriatric population by Clifton, Katherine, Kimmel, Jaime, Litton, Jennifer Keating, Tripathy, Debu, Karuturi, Meghan Sri

“…Abstract only…”
Get full text

Outcome of patients with breast cancer and a germline BRCA mutation in a prospective cohort by Arun, Banu, Gutierrez Barrera, Angelica, Layman, Rachel M., Gruschkus, Stephen K., Bedrosian, Isabelle, Albarracin, Constance T., Barcenas, Carlos Hernando, Valero, Vicente, Litton, Jennifer Keating, Tripathy, Debu

“…Abstract only 1544 Background: There are limited large prospective single institution studies on outcome of breast cancer in patients with germline BRCA1 and…”
Get full text

The incidence and impact of brain metastasis in patients with hereditary BRCA1/2 mutated invasive breast cancer in a prospectively followed cohort by Garber, Haven, Lehner, Michael, Raghavendra, Akshara Singareeka, Gutierrez-Barrera, Angelica M., Tripathy, Debu, Litton, Jennifer Keating, Arun, Banu, Ibrahim, Nuhad K.

“…Abstract only 1096 Background: Previous reports suggest the incidence of brain metastasis is higher in patients with hereditary BRCA1 mutations compared to…”
Get full text

Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (g BRCA1/2 ) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study by Telli, Melinda L., Litton, Jennifer Keating, Beck, Joseph Thaddeus, Jones, Jason M., Andersen, Jay, Mina, Lida A., Brig, Raymond, Danso, Michael A., Yuan, Yuan, Symmans, William Fraser, Abbattista, Antonello, Noonan, Kay, Mata, Marielena, Laird, Douglas, Blum, Joanne Lorraine

“…Abstract only 554 Background: TALA is a poly(ADP-ribose) polymerase inhibitor approved as monotherapy for adult pts with g BRCA1/2-mutated HER2-negative…”
Get full text

Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial by Litton, Jennifer Keating, Ettl, Johannes, Hurvitz, Sara A., Martin, Miguel, Roche, Henri, Lee, Kyung-Hun, Goodwin, Annabel, Usari, Tiziana, Lanzalone, Silvana, Guenzel, Carolin, Blum, Joanne Lorraine, Rugo, Hope S.

“…Abstract only 1090 Background: In the EMBRACA trial (NCT01945775) of pts with germline BRCA1/2-mutated HER2-negative locally advanced/metastatic breast cancer…”
Get full text

Neoadjuvant talazoparib in patients with germline BRCA1/2 (g BRCA1/2 ) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study by Litton, Jennifer Keating, Beck, Joseph Thaddeus, Jones, Jason M., Andersen, Jay, Blum, Joanne Lorraine, Mina, Lida A., Brig, Raymond, Danso, Michael A., Yuan, Yuan, Abbattista, Antonello, Noonan, Kay, Chakrabarti, Jayeta, Czibere, Akos, Symmans, William Fraser, Telli, Melinda L.

“…Abstract only 505 Background: Talazoparib (TALA) is a poly(ADP-ribose) polymerase inhibitor approved as monotherapy for treating adult patients (pts) with g…”
Get full text

Characterization of long-term responders following treatment with talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 embraca trial by Ettl, Johannes, Rugo, Hope S., Hurvitz, Sara A., Martin, Miguel, Roche, Henri, Lee, Kyung-Hun, Goodwin, Annabel, Usari, Tiziana, Lanzalone, Silvana, Guenzel, Carolin, Blum, Joanne Lorraine, Litton, Jennifer Keating

“…Abstract only 1029 Background: In the EMBRACA trial (NCT01945775), the poly(ADP-ribose) polymerase inhibitor (PARPi) TALA significantly improved…”
Get full text

Adjuvant or neoadjuvant chemotherapy in early stage triple negative breast cancer (TNBC) comparison of outcomes in both BRCA positive and BRCA negative patients by Clifton, Katherine, Gutierrez Barrera, Angelica, Ma, Junsheng, Bassett, Roland L., Litton, Jennifer Keating, Arun, Banu

“…Abstract only 576 Background: NSABP Protocol B-18 was a randomized trial which found no statistically significant difference in overall survival (OS) in…”
Get full text

Outcomes related to delayed initiation of anti-HER 2 therapy in pregnant HER2 positive breast cancer patients by Oke, Oluchi, Warneke, Carla L., Chavez-Mac Gregor, Mariana, Milbourne, Andrea, Litton, Jennifer Keating

“…Abstract only e12059 Background: Overexpression of HER2 is associated with aggressive breast cancers. In non-pregnant HER2+ breast cancer patients, anti-HER2…”
Get full text

A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations by Aftimos, Philippe Georges, Oliveira, Mafalda, Punie, Kevin, Boni, Valentina, Hamilton, Erika P., Gucalp, Ayca, Shah, Payal D, de Miguel, Maria J., Sharma, Priyanka, Bauman, Lisa, Campeau, Eric, Attwell, Sarah, Snyder, Margo, Norek, Karen, Johnson, Emily, Silverman, Michael H., Lakhotia, Sanjay, Domchek, Susan M., Litton, Jennifer Keating, Robson, Mark E.

“…1023 Background: Metastatic triple negative breast cancer (mTNBC) is an aggressive and heterogeneous cancer with limited therapeutic options. PARP inhibitors…”
Get full text

Real-world outcomes of genetic testing in a GU genetics clinic and evaluation of current guidelines by Pace, Annelise, Woodson, Ashley Henriksen, Slack-Tidwell, Rebecca, Daniels, Molly S., Pilie, Patrick Glen, Litton, Jennifer Keating, Hoskovec, Jennifer M., Jonasch, Eric

“…Abstract only 668 Background: Several known hereditary cancer syndromes confer an increased risk for genitourinary (GU)-related malignancies. Various…”
Get full text

Abstract P2-16-08: Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443) by Seth, Sahil, Huo, Lei, Vasaikar, Suhas, Rauch, Gaiane, Lim, Bora, White, Jason, Adrada, Beatriz, Piwnica-Worms, Helen, Ueno, Naoto T, Thompson, Alastair Mark, Mittendorf, Elizabeth, Tripathy, Debashish, Litton, Jennifer Keating, Symmans, William Fraser, Draetta, Giulio, Futreal, Andrew, Chang, Jeffrey, Moulder, Stacy

“…Background: The heterogeneity of TNBC results in a spectrum of responses to NAST: 30-40% of patients (pts) have pathologic complete response (pCR) with…”
Get full text

High incidence of germline BRCA mutation in patients with ER low‐positive/PR low‐positive/HER‐2 neu negative tumors by Sanford, Rachel A., Song, Juhee, Gutierrez‐Barrera, Angelica M., Profato, Jessica, Woodson, Ashley, Litton, Jennifer Keating, Bedrosian, Isabelle, Albarracin, Constance T., Valero, Vicente, Arun, Banu

“…BACKGROUND The 2015 National Comprehensive Cancer Network guidelines recommend that genetic counseling and germline BRCA mutation testing be offered to women…”
Get full text

The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC) by Abuhadra, Nour, Chang, Chia-Chi, Yam, Clinton, White, Jason B, Ravenberg, Elizabeth, Lim, Bora, Ueno, Naoto T., Litton, Jennifer Keating, Arun, Banu, Damodaran, Senthil, Murthy, Rashmi Krishna, Ibrahim, Nuhad K., Hortobagyi, Gabriel N., Valero, Vicente, Tripathy, Debu, Thompson, Alastair Mark, Mittendorf, Elizabeth A., Huo, Lei, Moulder, Stacy L., Jenq, Robert R.

“…Abstract only 590 Background: The impact of gut microbiome on tumor biology, progression and response to immunotherapy has been shown across cancer types…”
Get full text

Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC) by Yam, Clinton, Mittendorf, Elizabeth A., Sun, Ryan, Huo, Lei, Damodaran, Senthil, Rauch, Gaiane M, Candelaria, Rosalind P, Adrada, Beatriz E, Seth, Sahil, Symmans, William Fraser, Murthy, Rashmi Krishna, White, Jason B, Ravenberg, Elizabeth, Clayborn, Alyson, Prabhakaran, Sabitha, Valero, Vicente, Thompson, Alastair Mark, Tripathy, Debu, Moulder, Stacy L., Litton, Jennifer Keating

“…Abstract only 592 Background: Neoadjuvant anti-PD-(L)1 therapy confers an improvement in pathological complete response (pCR) rate in unselected TNBC. However,…”
Get full text

Short breast MRI screening trial in women at high-risk for breast cancer by Scoggins, Marion, Dogan, Basak, Ma, Jingfei, Wei, Wei, Song, Jong Bum, Candelaria, Rosalind P, Litton, Jennifer Keating, Arun, Banu

“…Abstract only e13049 Background: The American Cancer Society (ACS) recommends yearly breast MRI (BMRI) in addition to mammography for women with high breast…”
Get full text